Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of ...

Health Canada approves Hikma Pharma’s Kloxxado nasal spray 8 mg for treatment of known or suspected opioid overdose: London Monday, March 24, 2025, 13:00 Hrs [IST] Hikma Pharmac ...

March 20, 2025 (GLOBE NEWSWIRE) — Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg, by ...

KLOXXADO® delivers 8 mg of naloxone hydrochloride per spray in a ready to use nasal spray to reverse the effects of opioid overdose. “The approval of KLOXXADO® Nasal Spray will provide ...

KLOXXADO® delivers 8 mg of naloxone hydrochloride per spray in a ready to use nasal spray to reverse the effects of opioid overdose.

The Food and Drug Administration (FDA) has expanded the list of medicines for non-communicable diseases (NCDs) exempted from ...

A warm summer night, the hum of mosquitoes filling the air, and you, slathering on DEET, waving your arms like a windmill, ...

Hikma Pharmaceuticals (HKMPF) announces the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected ...

The pharmacokinetics of promethazine hydrochloride after administration ... healthy volunteers were given two 12.5-mg promethazine rectal suppositories, one 25-mg suppository, one 50-mg ...

In a major leadership transition, HCL Group founder Shiv Nadar has transferred ... On Friday, Lupin launched rivaroxaban tablets USP, 2.5 mg, in the US market. This was followed after the final ...